News & Views

Can FGF-23 predict clinical outcomes in CKD?

Numerous reports have linked elevated FGF-23 levels to the main adverse clinical outcomes in CKD: progression to end-stage renal disease (ESRD), cardiovascular disease, and death. Cross-sectional studies have also shown that increased FGF-23 levels in patients with CKD are associated with adverse systemic effects, increased mortality and deterioration of renal…

Read more
Professor Adrian Covic
Expert article by:
Professor Adrian Covic

Date of publication:
August 13, 2012

News & Views

The clinical significance of FGF-23 in CKD

A proliferation of studies linking excess levels of the endocrine hormone fibroblast growth factor 23 (FGF-23) to adverse renal and cardiovascular outcomes in patients with Chronic Kidney Disease (CKD) is setting the stage for new clinical trials, which could lead to FGF-23 becoming an important marker and/or therapeutic target in…

Read more
Professor Adrian Covic
Expert article by:
Professor Adrian Covic

Date of publication:
July 30, 2012

News & Views

CompAct Survey results of the ERA-EDTA 2012

The CompAct Survey started in November 2011 at the ASN congress in Philadelphia. Now the survey was conducted at the ERA-EDTA congress in Paris in May 2012. At this occasion 86 healthcare professionals participated and the overall results so far have been analyzed: In general, the survey results correspond to…

Read more

Date of publication:
July 23, 2012

News & Views

Our thoughts on the ERA-EDTA Congress 2012

Over 8.500 delegates descended on Paris in the early summer sun for the ERA-EDTA Congress 2012. A few key topics in CKD-MBD received valuable discussion during the sessions on Friday and Saturday. Here are some of our highlights: In Friday’s late breaking clinical trial session, former ERA-EDTA president Prof. Jorge B….

Read more

Date of publication:
June 28, 2012

News & Views

Does phosphate binder treatment confer a survival benefit on treated patients? (Part II)

Until recently, evidence has been lacking that directly associates phosphate binder treatment with reduced mortality. In Part 1 of our article, we examined several recent studies that have investigated this association. Two studies [1] [2] in particular have shown mortality reductions of 25% associated with phosphate binder use. However, these and…

Read more

Date of publication:
June 1, 2012

News & Views

What are the causes of patient non-adherence to hyperphosphatemia treatment? (Part II)

Previously in our series on non-adherence, we assessed how improved patient education could positively impact the 50%+ non-compliance rate in hyperphosphatemia treatment. In this article we assess the following questions: How does a patient’s drug preference impact their adherence to treatment? Why do patients prefer some treatments over others? How does…

Read more

Date of publication:
May 29, 2012

News & Views

What are the causes of patient non-adherence to hyperphosphatemia treatment? (Part I)

Non-adherence to treatment regimens in hyperphosphatemia is a significant treatment challenge, with over 50% of patients non-compliant by some measures. In this series of articles we examine the factors that contribute to this low adherence, including: patient demographics; patient education and guidance; psychosocial factors, such as a patient’s perception of…

Read more

Date of publication:
May 16, 2012

News & Views

First results of the CompAct Survey

The COMPACT SURVEY started in November 2011. At the occasion of the ASN congress in Philadelphia, USA, 38 healthcare professionals participated and the overall results so far have been analyzed: The participating physicians are convinced that dialysis patients do not know about the consequences of hyperphosphatemia and that this is…

Read more

Date of publication:
May 2, 2012

Login

You are about to leave Compact-Renal.com

Clicking the "Continue" link below will take you to an external website. Compact Renal is not responsible for the contents of any external website. Compact Renal is providing these links to you as a convenience, and the inclusion of any links does not imply endorsement of the linked site by Compact Renal.

Do you wish to continue?

Continue Cancel